Healthcare · Drug Manufacturers - Specialty & Generic
Price
$42.07
Market Cap
$1.6B
Employees
382
Beta
0.28
Avg Volume
773,893
CEO
Mark L. Baum
Business Description
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-300.50
Stock Price: $42.07
EPS (Diluted): -0.14
EPS (Diluted): -0.14
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
34.35
Stock Price: $42.07
Total Equity: $52.45M
Shares: 36,760,461
Total Equity: $52.45M
Shares: 36,760,461
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
47.88
Market Cap: $1.57B
Total Debt: $244.07M
Cash: $72.93M
EBITDA: $41.36M
Total Debt: $244.07M
Cash: $72.93M
EBITDA: $41.36M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$2.0B
Market Cap: $1.57B
Total Debt: $244.07M
Cash: $72.93M
Total Debt: $244.07M
Cash: $72.93M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
6.61
Stock Price: $42.07
Revenue: $272.30M
Shares: 36,760,461
Revenue: $272.30M
Shares: 36,760,461
EV/Sales (Total value vs revenue — works when P/E can't)
API7.27
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
75.1%
Gross Profit: $204.37M
Revenue: $272.30M
Revenue: $272.30M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
14.2%
Operating Income: $38.61M
Revenue: $272.30M
Revenue: $272.30M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-1.9%
Net Income: -$5.14M
Revenue: $272.30M
Revenue: $272.30M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-9.8%
Net Income: -$5.14M
Total Equity: $52.45M
Total Equity: $52.45M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
51.5%
Operating Income: $38.61M
Tax Rate: -198.1%
Equity: $52.45M
Total Debt: $244.07M
Cash: $72.93M
Tax Rate: -198.1%
Equity: $52.45M
Total Debt: $244.07M
Cash: $72.93M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.20
Current Assets: $211.75M
Current Liabilities: $96.30M
Current Liabilities: $96.30M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
4.65
Short-Term Debt: $887,000
Long-Term Debt: $243.18M
Total Debt: $244.07M
Total Equity: $52.45M
Long-Term Debt: $243.18M
Total Debt: $244.07M
Total Equity: $52.45M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$7.41
Revenue: $272.30M
Shares: 36,760,461
Shares: 36,760,461
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.43
Total Equity: $52.45M
Shares: 36,760,461
Shares: 36,760,461
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$1.16
Operating CF: $43.86M
CapEx: -$1.10M
Shares: 36,760,461
CapEx: -$1.10M
Shares: 36,760,461
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $42.07
Stock Price: $42.07
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$5.14M
Net Income: -$5.14M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares HROW against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Cost of Revenue | $18.2M | $25.4M | $39.6M | $49.2M | $67.9M |
| Gross Profit | $54.3M | $63.2M | $90.6M | $150.4M | $204.4M |
| Operating Expenses | $52.6M | $61.3M | $90.1M | $141.5M | $165.8M |
| Operating Income | $1.6M | $1.9M | $431,000 | $8.8M | $38.6M |
| Net Income | -$18.0M | -$14.1M | -$24.4M | -$17.5M | -$5.1M |
| EBITDA | $5.1M | -$3.9M | $11.9M | $22.1M | $41.4M |
| EPS | $-0.69 | $-0.51 | $-0.75 | $-0.49 | $-0.14 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $42.2M | $96.3M | $74.1M | $47.2M | $72.9M |
| Total Current Assets | $60.7M | $118.3M | $139.1M | $189.7M | $211.8M |
| Total Assets | $98.3M | $157.4M | $311.8M | $389.0M | $399.5M |
| Current Liabilities | $9.7M | $18.6M | $49.3M | $91.3M | $96.3M |
| Long-Term Debt | $71.7M | $104.2M | $183.2M | $219.5M | $243.2M |
| Total Liabilities | $87.4M | $130.1M | $241.8M | $319.7M | $347.4M |
| Total Equity | $11.3M | $27.6M | $70.4M | $69.7M | $52.4M |
| Retained Earnings | -$95.4M | -$109.5M | -$133.9M | -$151.4M | -$156.5M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $5.1M | $1.7M | $3.8M | -$22.2M | $43.9M |
| Capital Expenditure | -$28.5M | -$7.8M | -$152.6M | -$38.7M | -$1.1M |
| Free Cash Flow | -$23.4M | -$6.1M | -$148.7M | -$60.9M | $42.8M |
| Acquisitions (net) | $9.8M | $0 | $0 | $0 | -$4.4M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $37.9M | $54.1M | -$22.2M | -$26.8M | $25.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 6:38pm (14h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$515.6M $468.2M – $545.2M
|
$706.8M $696.4M – $717.2M
|
$959.2M $897.1M – $1.0B
|
$1.1B $1.0B – $1.2B
|
| EBITDA |
$39.2M $35.6M – $41.5M
|
$53.8M $53.0M – $54.6M
|
$73.0M $68.3M – $77.0M
|
$83.6M $78.2M – $88.2M
|
| Net Income |
$92.9M $44.7M – $118.5M
|
$171.9M $105.5M – $185.6M
|
$251.8M $230.6M – $269.7M
|
$303.3M $277.7M – $324.8M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:15pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +22.2% | +47.0% | +53.3% | +36.4% |
| Gross Profit Growth | +16.5% | +43.3% | +66.1% | +35.9% |
| Operating Income Growth | +18.9% | -77.5% | +1,946.9% | +337.6% |
| Net Income Growth | +21.8% | -73.3% | +28.4% | +70.6% |
| EBITDA Growth | -177.1% | +403.6% | +85.2% | +86.9% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for HROW — it's generated by the pipeline (
market-narrative step).
No community reviews yet for HROW.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30